M
Masakazu Toi
Researcher at Kyoto University
Publications - 658
Citations - 28522
Masakazu Toi is an academic researcher from Kyoto University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 69, co-authored 578 publications receiving 23200 citations. Previous affiliations of Masakazu Toi include The Breast Cancer Research Foundation & Tokyo Metropolitan Komagome Hospital.
Papers
More filters
Journal ArticleDOI
Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast Cancer
TL;DR: It was suggested that the expression of VEGF is closely associated with the promotion of angiogenesis and with early relapse in primary breast cancer.
Journal ArticleDOI
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
David Cameron,Julia Brown,Rebecca Dent,Christian Jackisch,John R. Mackey,Xavier Pivot,Guenther G. Steger,Thomas M. Suter,Masakazu Toi,Mahesh K. B. Parmar,Rita Laeufle,Young-Hyuck Im,Gilles Romieu,Vernon Harvey,Oleg Lipatov,Tadeusz Pienkowski,Paul Cottu,A. Chan,Seock-Ah Im,Peter Hall,Lida Bubuteishvili-Pacaud,Volkmar Henschel,Regula Deurloo,Celine Pallaud,Richard Bell +24 more
TL;DR: Bvacizumab cannot be recommended as adjuvant treatment in unselected patients with triple-negative breast cancer and exploratory biomarker assessment suggests that patients with high pre-treatment plasma VEGFR-2 might benefit from the addition of bevaczumab.
Journal ArticleDOI
Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression
TL;DR: It was concluded that MVD is a potent prognostic indicator in primary breast cancer and it was suggested that VEGF plays crucial roles in the promotion of angiogenesis in breast cancer.
Journal ArticleDOI
Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma.
TL;DR: Breakdown analysis stratified by nodal status showed that the vessel density was a significant prognostic indicator in node‐negative and node‐positive patients and Multivariate analysis indicated that the vessels density is an independent prognostic indicators in primary breast‐cancer patients.
Journal ArticleDOI
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
Edith A. Perez,Carlos H. Barrios,Wolfgang Eiermann,Masakazu Toi,Young-Hyuck Im,Pierfranco Conte,Miguel Martin,Tadeusz Pienkowski,Xavier Pivot,Howard A. Burris,Jennifer A. Petersen,Sven Stanzel,Alexander Strasak,Monika Patre,Paul Ellis +14 more
TL;DR: T-DM1 showed noninferior, but not superior, efficacy and better tolerability than did taxane plus trastuzumab for first-line treatment of HER2-positive, advanced breast cancer.